Home/Biosimilar Atlas/Infliximab/Reliance Life Sciences infliximab

Reliance Life Sciences infliximab

Infliximab biosimilar developed by Reliance Life Sciences. Reference product Remicade.

Brands by market: Brand not published by CDSCO (India) · Commercial partner or holder: Reliance Life Sciences · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCNot listed
CDSCOMar 2014permitted
EDENot listed
Approved or registered in 1 of 7 markets
Connections
InfliximabmoleculeReliance Life Sciencesdeveloper1 of 7markets0trials behind it13other products, same developer2rival developers in its markets

About Reliance Life Sciences infliximab

Reliance Life Sciences received the first infliximab permission in India, in March 2014, covering arthritis, bowel disease and psoriasis. It remains the only infliximab made in India; the other Indian entries are imports.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

MHRA

United Kingdom

Not listed by MHRA.

PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Reliance Life Sciences Pvt Ltd
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Mar 2014
Application or permission
MF-61/2014; BULK-62/2014
Indications as licensed
RA, AS, PsA, psoriasis, Crohn's disease, UC
Presentations
100 mg lyophilised vial
Remarks
First infliximab biosimilar permitted in India.
Source
S014 (CDSCO) · checked Sep 2026
EDE

United Arab Emirates

Not listed by EDE.

Other developers in the same markets

Where Reliance Life Sciences infliximab holds an approval, these are the other infliximab biosimilars approved in that market.

MarketRivalsDevelopers (product)
CDSCO2Biocad (Biocad infliximab), Celltrion (Remsima / Inflectra)

Same developer, other molecules

Other biosimilars in the Atlas developed by Reliance Life Sciences: Reliance Life Sciences adalimumab, Reliance Life Sciences bevacizumab, Reliance Life Sciences darbepoetin alfa, Reliance Life Sciences denosumab, Reliance Life Sciences etanercept, Reliance Life Sciences follitropin alfa, Reliance Life Sciences golimumab, Reliance Life Sciences omalizumab, Reliance Life Sciences ranibizumab, Reliance Life Sciences rituximab, Reliance Life Sciences somatropin, Reliance Life Sciences trastuzumab, UstekiRel.

Chronology

Sources

All infliximab biosimilars

Planning infliximab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.